5/27/2023 0 Comments Silo wellness![]() ![]() If the future is pharma, we have an asset for you as well. “In other words, if the future of psychedelic medicine is a state-by-state legalization akin to cannabis, we intend to have you covered. “We believe we will be the only company with deep roots in Oregon that is actively providing psilocybin to paying guests in the western hemisphere (Jamaica) while at the same time working a pharmaceutical opportunity (Dyscovry),” he said. The downstream goal is to bring regenerative medicine approaches to the treatment of IBS,” he added.Īrnold echoed the sentiment, talking about “a de-risking platform for psychedelic investors. ![]() ![]() “By Dyscovry's research team focusing on investigating a quantifiable anti- inflammatory effect of psychedelics, Dyscovry has embarked on the rigorous scientific investigation of enhanced biosynthesis of psilocybin, as an alternative therapeutic option to both naturally-occurring and chemically-synthesized psilocybin. MORE FROM FORBES Psychedelic Mushroom Shops Reach The Americas By Javier Hasse “We have intended to differentiate Dyscovry and de-risk our psychedelic pharmaceutical opportunity by assembling the key components to create a comprehensive pharmaceutical corporation with psilocybin and its derivatives targeting a physiological condition, IBS,” said CEO Gerard Lee “Dyscovry has the facilities, IP, clinical research, and the public and private collaborations required to begin to advance this initiative. Dyscovry’s management team, Brad Dottin and Gerard Lee, like to emphasize their company’s thoughtful approach to the emerging psychedelic pharmaceutical landscape. ![]()
0 Comments
Leave a Reply. |